GLP-1 insurance coverage, mapped honestly

Does insurance cover GLP-1s for weight loss?

Sometimes — and the deciding variable is your employer’s plan design, not the insurer’s name. Aetna, Cigna, UnitedHealthcare, BCBS-family plans, Kaiser, and Humana all administer plans that cover weight-loss GLP-1s and plans that exclude them; asking “does Cigna cover Wegovy” has no single true answer. The question that does: is Wegovy or Zepbound on my plan’s formulary for weight management, and what utilization management applies? Your Summary of Benefits, the formulary PDF, or one call to the member line answers it in minutes.

Medicare, stated precisely (plan year 2026, recorded 2026-08-24)

Part D excludes drugs used for weight loss — a statutory exclusion, not a formulary choice. The working exception: where a GLP-1 carries an approved non-weight-loss indication that applies to you — notably Wegovy’s cardiovascular-risk indication for patients with established CV disease and elevated weight, or Zepbound’s obstructive-sleep-apnea indication — Part D plans can cover it for that indication. Policy in this area has been actively debated; confirm the current-year rule against Medicare.gov before relying on it.

Medicaid, TRICARE, VA

Medicaid: state-by-state — a minority of states cover weight-loss GLP-1s with prior authorization, and criteria change annually; your state’s preferred-drug list is the source of truth. TRICARE and VA: case-by-case with documented criteria and step therapy — the prescribing clinician’s notes carry these approvals or lose them.

Prior authorization and appeals — the part that actually wins coverage

PA denials are the default first response, and appeals overturn a meaningful share of them. The winning file: documented BMI history, comorbidities (hypertension, dyslipidemia, prediabetes, OSA), prior structured weight-management attempts, and step-therapy compliance where required. Denied? Request the denial reason in writing, match your appeal to that exact reason, include clinician letters of medical necessity, and use your plan’s external-review right if the internal appeal fails — external review exists precisely because internal appeals under-approve.

Savings cards and manufacturer programs

Commercially insured (even when denied) may qualify for the Zepbound or Wegovy savings cards — terms and caps change; the manufacturer pages are authoritative. Federal-program members (Medicare, Medicaid, TRICARE) are excluded from manufacturer copay cards by law. Cash routes: NovoCare’s Wegovy program ($199 qualifying first fills, then $349/mo; pill tiers $149–$299) and LillyDirect’s Zepbound vials ($299–$449 conditional, to $699 off-offer) — verified 2026-08-25, conditions on each row, on the brand list.

The hybrid play, and the honest fallback

Insurance can cover the visit while you pay cash for medication — useful when the consult is covered but the drug is excluded. And when coverage truly isn’t there, the self-pay floor is the without-insurance page: verified compounded from $69/mo — not FDA-approved, which is the trade, stated plainly.

Dating discipline: every coverage fact above is plan-year 2026, recorded 2026-08-24. Employer formularies differ from carrier defaults; nothing here overrides your plan documents.